Biopharma

This content is intended for Republic of Ireland Healthcare Professionals only. For Northern Ireland, please visit the Fresenius Kabi UK website here

 

Prescribing information is available in the downloads section below. Adverse event reporting details are also available at the bottom of this webpage.

Bomyntra®▼(denosumab)

Conexxence®▼ (denosumab)

Otulfi ®▼(ustekinumab)

Idacio® (adalimumab)

Tyenne®▼(tocilizumab)

Filename
Idacio® Prescribing Information.pdf
Size
1 MB
Format
pdf
Idacio® Prescribing Information
Filename
Tyenne Prescribing Information.pdf
Size
2 MB
Format
pdf
Tyenne® Prescribing Information
Filename
Otulfi® Prescribing Information.pdf
Size
157 KB
Format
pdf
Otulfi® Prescribing Information
Filename
Bomyntra® Prescribing Information.pdf
Size
238 KB
Format
pdf
Bomyntra® Prescribing Information
Filename
Conexxence Prescribing Information.pdf
Size
210 KB
Format
pdf
Conexxence® Prescribing Information
Adverse events should be reported.
Reporting forms and information can be found at:
www.hpra.ie/homepage/about-us/report-an-issue
Adverse events should also be reported to Fresenius Kabi Limited, Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT Tel +444 (0) 800 090 2513

Job code:IE-BOM-2600003

Date of preparation: April 2026